ADAnne Debourgogne

Anne Debourgogne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne Debourgogne has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Anne-Lyse Babin

    UR 7300 SIMPA, Stress Immunity Pathogens Laboratory, Faculty of Medicine, Lorraine University, 9 Avenue de la Forêt de Haye, F-54500 Vandœuvre-lès-Nancy, France

    2 shared publications
  • Claire Cottrel

    Université de Lorraine, SIMPA, F-54000 Nancy, France; Université de Lorraine, CHRU-Nancy, Laboratoire de Microbiologie, F-54000 Nancy, France

    2 shared publications
  • Jean-Pol Frippiat

    UR SIMPA, Stress Immunity Pathogens Laboratory, Faculty of Medicine, Lorraine University, Vandœuvre-lès-Nancy, France

    2 shared publications
  • A Berceanu

    Hematology Department, Besançon Hospital , Besançon

    1 shared publication
  • A Charmillon

    Infectious Diseases Department in Charge of Mobile Infectiology Team, CHRU de Nancy-Brabois , Vandoeuvre-lès-Nancy

    1 shared publication
  • Agnes Melone

    CHRU-Nancy, Biopathologie, Université de Lorraine , Nancy

    1 shared publication

Latest Publications

  • Typage moléculaire du complexe d'espèces Fusarium solani et détermination de son mécanisme de résistance au voriconazole

    by Anne Debourgogne

    Le complexe d'espèces Fusarium solani regroupe des champignons phytopathogènes également impliqués en pathologie humaine dans des infections parfois profondes et souvent de mauvais pronostic. Dans un premier temps, une méthode de MLST, s'appuyant sur 5 gènes de ménage a donc été développée. Validée sur 51 isolats épidémiologiquement distincts, cette méthode stable et reproductible présente un pouvoir discriminant de 99,1 %. Après comparaison à la technique de référence utilisée en phylogénie, un schéma consensus à 8 loci a été proposé. Dans un second temps, une étude de la sensibilité de ce pathogène à l'amphotéricine B et au voriconazole a été menée par deux techniques d'évaluation des CMI : microdilution CLSI M38-A2 et bandelettes E-test. Devant le paradoxe entre une sensibilité diminuée in vitro au voriconazole et la recommandation de cette molécule pour le traitement curatif de la fusariose humaine, des mécanismes de résistance ont été exploré. L'hypothèse d'un phénomène d'efflux n'a pas été retenue alors que celle d'une modification de la cible, la 14 alpha stérol déméthylase, peut être envisagée après la description de différentes mutations pour les isoformes CYP51A, B et C

  • Open Access

    Compassionate Use of Olorofim for Invasive Mold Infections: A Nationwide Observational Study in France

    by V Esnault, C Godet, D Garcia-Hermoso, A Charmillon, P Parize, C Bonnal, A Debourgogne, F Morio, M E Bougnoux, E Dannaoui, et al.

    Background: The increasing incidence of resistant invasive mold infections (IMIs) has highlighted the need for novel antifungal agents. Olorofim, a first-in-class orotomide, has shown promising efficacy in a recent phase II study, but clinical data remain limited. Methods: We conducted a retrospective multicenter cohort study in France, including all patients who received olorofim under compassionate use for proven or probable non-Mucorales IMIs. Eligible patients had IMIs refractory to or intolerance to standard antifungals or no effective treatment options. Efficacy was defined as mycological and clinical control of infection; safety was also assessed. Results: Between January 2020 and December 2023, 17 patients (median age, 39 years) received olorofim. Underlying conditions included primary immunodeficiency (n = 4) and lung transplantation (n = 5). Sites of infection included the lung (88.2%) and the central nervous system (23.5%), with 5 cases of disseminated disease. In total, 23 strains were identified, mostly Aspergillus fumigatus (34.8%) and Microascus spp (13%). The median duration of prior antifungal therapy was 9.1 months. Olorofim was used primarily for refractory IMIs (70.6%) and in combination with other antifungals in 82.4% of cases. Olorofim minimum inhibitory concentrations were ≤0.5 mg/L in the 8 available isolates. Among 15 evaluable patients, 5 (33.3%) achieved clinical and mycological success, 7 (46.7%) had partial responses, and 3 (20%) experienced treatment failure. The 3-month mortality rate was 29.4% (5 of 17). No severe adverse events were reported. Conclusions: Olorofim exhibited potential efficacy and good tolerability in patients with refractory IMIs. Further data from ongoing clinical trials are needed to confirm these findings.


  • Open Access

    When Emerging Fungal Infections Mimic Tuberculosis: First Reported Case of Invasive Emergomyces europaeus Infection in a Man With Immunocompromise Living in France

    by Claire Cottrel, Natesan Ramsamy, Emilie Fruquière, Agnes Melone, Fanny Lanternier, Dea Garcia-Hermoso, Anne Debourgogne

    Emergomycosis is an emerging thermally dimorphic fungal infection primarily observed in individuals with HIV and is associated with cutaneous, pulmonary, or disseminated manifestations. We report the first case of invasive infection by Emergomyces europaeus involving both the lungs and bone marrow in a person with immunocompromise, identified through molecular tools.

  • Open Access

    In vivo Fusarium virulence and efficacy of voriconazole in a Galleria mellonella model of invasive fusariosis

    by Claire Cottrel, Pierre Vermeulen, Anne-Lyse Babin, Jean-Pol Frippiat, Marie Machouart, Guillaume Gauchotte, Anne Debourgogne

  • Clustered cases of Candida auris colonization: Roles of the infection prevention and control department and the mycology laboratory in controlling transmission

    by Claire Cottrel, Marie Regad, Charlotte Arnal, Sandrine Henard, Marie Desnos-Olivier, Alain Lozniewski, Alexandre Alanio, Anne-Claire Bursztejn, Julie Lizon, Anne Debourgogne

    Candida auris is an emerging yeast that is responsible for outbreaks via nosocomial transmission. This study describes two cases of C. auris colonization, with confirmed interhospital transmission in the absence of travel history for the index case, although multiple risk factors were present. The role of the infection prevention and control department is essential in implementing barrier measures to limit yeast transmission, whereas the mycology laboratory plays a crucial role in the rapid and effective detection of potential contact cases, as well as environmental contamination.


  • Open Access

    Reevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients: Current Evidence and Future Directions

    by Emmanuel Novy, Mathieu Esposito, Anne Debourgogne, Claire Roger

    Intra-abdominal candidiasis (IAC) is associated with significant diagnostic and therapeutic challenges in critically ill patients. Traditional fungal cultures are slow, delaying appropriate antifungal treatment. (1,3)-β-D-glucan (BDG), a component of the fungal cell wall, has emerged as a potential biomarker for IAC, but its use in ICU settings is complicated by frequent false-positives results from invasive procedures and underlying conditions. This review examines the diagnostic value of BDG when present in serum and peritoneal fluid. While serum BDG is effective for excluding invasive fungal infections like candidemia, its specificity for IAC remains low in critically ill patients. Recent studies suggest that BDG levels in peritoneal fluid may provide better diagnostic accuracy, distinguishing IAC from bacterial peritonitis with higher specificity. We discuss the advantages, limitations, and practical aspects of BDG testing, emphasizing the potential of peritoneal BDG as a complementary tool. Further research is needed to refine diagnostic thresholds, validate its clinical utility, and establish the role of peritoneal BDG in improving timely, targeted antifungal treatment for IAC.


  • Open Access

    Interactions between Bacteria and Aspergillus fumigatus in Airways: From the Mycobiome to Molecular Interactions

    by Anne Debourgogne, Lorra Monpierre, Khadeeja Adam Sy, Isabel Valsecchi, Jean-Winoc Decousser, Françoise Botterel

    Interactions between different kingdoms of microorganisms in humans are common but not well described. A recent analysis of the mycobiome has described the presence of different fungi and their positive and/or negative interactions with bacteria and other fungi. In chronic respiratory diseases, these different microorganisms form mixed biofilms to live inside. The interactions between Gram-negative bacteria and filamentous fungi in these biofilms have attracted more attention recently. In this review, we analyse the microbiota of the respiratory tract of healthy individuals and patients with chronic respiratory disease. Additionally, we describe the regulatory mechanisms that rule the mixed biofilms of Aspergillus fumigatus and Gram-negative bacteria and the effects of this biofilm on clinical presentations.


  • Open Access

    Simulated Microgravity Created Using a Random Positioning Machine Induces Changes in the Physiology of the Fusarium solani Species Complex

    by Maurine D’agostino, Anne-Lyse Babin, Marie Zaffino, Jean-Pol Frippiat, Marie Machouart, Anne Debourgogne

    Fusarium is a phytopathogenic fungus involved in human pathology and is present in space stations. It is essential to understand the effects of microgravity on the physiology of this fungus to determine the potential risks to the health of crew members and to propose the necessary countermeasures. This study aimed to determine changes in the physiological parameters of the Fusarium solani species complex under simulated microgravity generated using a random positioning machine (RPM) and phenotypic approaches. We observed increased growth, spore production, and germination while biofilm production was reduced under RPM exposure. These in vitro data show the importance of further studying this fungus as it has been repeatedly demonstrated that microgravity weakens the immune system of astronauts.


  • Open Access

    CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium

    by Pierre Vermeulen, Arnaud Gruez, Anne-Lyse Babin, Jean-Pol Frippiat, Marie Machouart, Anne Debourgogne

    Members of Fusarium solani species complex (FSSC) are cosmopolitan filamentous fungi responsible for invasive fungal infections in immunocompromised patients. Despite the treatment recommendations, many strains show reduced sensitivity to voriconazole. The objective of this work was to investigate the potential relationship between azole susceptibility and mutations in CYP51 protein sequences. Minimal inhibitory concentrations (MICs) for azole antifungals have been determined using the CLSI (Clinical and Laboratory Standards Institute) microdilution method on a panel of clinical and environmental strains. CYP51A, CYP51B and CYP51C genes for each strain have been sequenced using the Sanger method. Amino acid substitutions described in multiple azole-resistant Aspergillus fumigatus (mtrAf) strains have been sought and compared with other Fusarium complexes’ strains. Our results show that FSSC exhibit point mutations similar to those described in mtrAf. Protein sequence alignments of CYP51A, CYP51B and CYP51C have highlighted different profiles based on sequence similarity. A link between voriconazole MICs and protein sequences was observed, suggesting that these mutations could be an explanation for the intrinsic azole resistance in the genus Fusarium. Thus, this innovative approach provided clues to understand low azole susceptibility in FSSC and may contribute to improving the treatment of FSSC infection.


  • Open Access

    Molecular Diagnosis of Disseminated Adiaspiromycosis Due toEmmonsia crescens

    by J.-M. Dot, A. Debourgogne, J. Champigneulle, Y. Salles, M. Brizion, J. M. Puyhardy, J. Collomb, F. Plénat, M. Machouart

    Emmonsia crescensis a saprophytic fungus that is distributed worldwide, causing diseases mostly in rodents. It has also been described, though rarely, as an etiologic agent of pulmonary pathology in humans, potentially leading to death. A case of pulmonary adiaspiromycosis is reported in a 30-year-old immunocompetent man. The patient presented with a history of several weeks of weakness, cough, fever, and weight loss of 10 kg. Clinical and radiographic findings showed pulmonary lesions consistent with tuberculosis or histoplasmosis, but no pathogen was found with classical microbiological procedures. The diagnosis of adiaspiromycosis due toEmmonsia crescenswas initially made using molecular biology techniques. Histological observations subsequently confirmed the presence of adiaspores in granulomas. To our knowledge, this is the first case of adiaspiromycosis diagnosed by PCR and sequencing. The patient was treated with itraconazole and was seen at 1 month with symptomatic improvement. Here we will discuss this rare fungal infection and its difficult treatment and diagnosis. As represented in this case, molecular biology is a powerful method to optimize diagnostic tests and therefore improve the care of the infected patient.